Trial ID 21219 | Maryland Oncology Hematology Trial ID 21219 – Maryland Oncology Hematology

Trial ID 21219

Trial Information - Phase II

RMC-4630-03: A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Disease Specifics: NSCLC

Protocol ID: RMC-4630-03

Sponsor: Revolution Medicines, Inc.

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Status

STAR Trial

Sponsor

Revolution Medicines, Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology